Filing Overview
NLS Pharmaceutics Ltd., a Swiss foreign private issuer filing on Form 6-K, reported an event for May 8, 2023, in its third Form 6-K report for May 2023. The filing concerns a change in senior financial management and does not provide financial results.
Key Financial Metrics
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change
Effective May 8, 2023, Keith Harrison Dewedoff was appointed Interim Chief Financial Officer following the resignation of Chad Hellman.
Mr. Dewedoff has more than 20 years of life sciences experience and has held finance leadership roles at biotech startups and publicly traded companies. He also serves as a CFO and advisor for Danforth Advisors, LLC.
Guidance, Risks, and Unusual Items
The filing does not provide financial guidance, operating outlook, management forecasts, new risk disclosures, contingencies, or details of unusual financial items.
The CFO transition may be relevant to financial reporting, financing activities, and corporate operations, but the filing does not describe any expected impact.
Investor Verification Items
- Verify the circumstances and effective date of Chad Hellman’s resignation.
- Monitor the duration of Mr. Dewedoff’s interim appointment and any subsequent permanent CFO appointment.
- Review subsequent filings for changes to financial reporting, financing plans, liquidity, or corporate strategy.
- Note that the report is incorporated by reference into the company’s specified Form F-3 registration statements.